Summary & Overview
HCPCS J9353: Injection, margetuximab-cmkb, 5 mg
HCPCS Level II code J9353 denotes the injection of margetuximab-cmkb in 5 mg units, representing administration of a targeted monoclonal antibody therapy. As biologic oncology agents become more common, accurate coding for unit-based HCPCS drugs is important for billing continuity and national payment reporting. This code matters for hospitals, oncology practices, and payers because it determines how doses are documented, billed, and aggregated for cost and utilization monitoring.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage considerations, common modifiers used with HCPCS drug codes, and clinical context related to infusion-based monoclonal antibody therapy. The publication summarizes national benchmarks where available, outlines typical sites of service for administration, and highlights coding and billing elements relevant to unit-based biologic drugs.
The reader will learn how J9353 is applied in practice, what information payers commonly require for payment, and where to look for policy updates affecting oncology injectables. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J9353 represents the injection of margetuximab-cmkb in a unit of 5 mg. This code is used to report administration of the monoclonal antibody margetuximab-cmkb, which is delivered by intravenous injection.
Service Type: Therapeutic monoclonal antibody infusion/injection
Typical Site of Service: Hospital outpatient department, physician office infusion suite, or outpatient infusion center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J9353 is an adult with HER2-positive metastatic breast cancer or HER2-positive advanced breast carcinoma who has progressed on or is intolerant to prior anti-HER2 therapies. The clinical workflow begins with an oncology consultation documenting tumor HER2 status and prior treatment history. Pre-infusion evaluation includes vital signs, chemotherapy consent, review of prior infusion reactions, baseline labs (CBC, CMP), and assessment for infusion center eligibility. The medication is prepared by pharmacy as an intravenous infusion from the 5 mg vial strength and administered in an outpatient infusion suite or hospital outpatient department by oncology nursing staff under physician supervision. During infusion, nursing monitors for hypersensitivity, infusion-related reactions, and vital sign changes. Post-infusion observation and documentation of any adverse events, medication lot numbers, and administered dose are recorded in the medical record and the infusion administration record. Billing uses J9353 per 5 mg unit with appropriate diagnosis linkages and applicable modifiers for payer adjudication.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard billing. | Use when no special circumstances apply. |